Company intelligence / Profile preview

Atia Vision

Campbell, California, United Statesatiavision.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Atia Vision is developing the OmniVu Lens System, a next-generation modular dual-optic intraocular lens designed to restore dynamic range of vision for patients undergoing cataract surgery. The system has shown promising results in over 75 eyes internationally with up to three years of follow-up—100% achieved 20/20 or better uncorrected distance vision, with contrast sensitivity and patient satisfaction comparable to monofocal lenses. The company received FDA Investigational Device Exemption approval in May 2025 to begin a US clinical feasibility study[4][5][8][10].

Therapeutic areas: Ophthalmology
Modalities: Device (specifically intraocular lens)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

OmniVu

Phase 1

Indications: Cataracts, Presbyopia

Beyond the preview

Go deeper on Atia Vision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atia Vision.

Explore the full profile